Detalhe da pesquisa
1.
Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study.
Am J Gastroenterol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38275272
2.
Gastric Cancer Screening in Common Variable Immunodeficiency.
J Clin Immunol
; 38(7): 768-777, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30219982
3.
Ulcerative colitis and acute perimyocarditis.
Med J Aust
; 216(11): 559-561, 2022 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603738
4.
Hygiene Hypothesis: Is the Evidence the Same All Over the World?
Dig Dis
; 34(1-2): 35-42, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26982573
5.
Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific.
Gut
; 64(7): 1063-71, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25217388
6.
Inflammatory Bowel Disease Environmental Risk Factors: A Population-Based Case-Control Study of Middle Eastern Migration to Australia.
Clin Gastroenterol Hepatol
; 13(8): 1453-63.e1, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25771246
7.
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Aliment Pharmacol Ther
; 59(11): 1312-1334, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651771
8.
Inflammatory bowel disease environmental risk factors versus genetics based on migration epidemiological studies.
J Gastroenterol Hepatol
; 33 Suppl 3: 22, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187554
9.
Capsule endoscopy retention in the upper esophagus: A comprehensive literature review.
Medicine (Baltimore)
; 102(36): e35113, 2023 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37682178
10.
Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol.
BMJ Open
; 13(10): e073071, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37788929
11.
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Therap Adv Gastroenterol
; 15: 17562848221080793, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35282607
12.
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Aliment Pharmacol Ther
; 54(3): 292-301, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34151447
13.
Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
Aliment Pharmacol Ther
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38779926
14.
The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases.
Intest Res
; 16(3): 409-415, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30090040
15.
Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
Expert Opin Drug Saf
; 15(1): 53-63, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26560097
16.
Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases.
World J Gastroenterol
; 20(5): 1238-47, 2014 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24574798
17.
Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn's disease and ulcerative colitis.
J Crohns Colitis
; 8(10): 1237-45, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24662396